The Chemical Extrapyramidal Syndrome: Its Reduction with UK-738

Publisher Website
Google Scholar
Abstract
Consideration should be given to the prophylactic use of antiparkinsonian agents for the following patients: Dose. Those who will receive large amounts of the phenothiazine especially if relatively high doses are administered at the onset of treatment. Type of phenothiazine. Those who will receive drugs of the prochlorperazine type. Sex. Females are more prone to develop the EPS than males. Age. With the exception of dyskinesias, the EPS is more likely to occur in the older patients. Young people are more susceptible to the dyskinetic reactions. Patients who are likely to be disturbed by the distortions in body image that the EPS induces. The treatment of the EPS once clinical symptoms have developed can be satisfactorily carried out with UK-738 (N-ethyl-nortropine-benzhydrylether-hydrobromide). Generally small amounts (2-6 mg daily) suffice, however, much larger quantities of the agent are tolerated without disturbing anticholinergic effects. A liquid form of an antiparkinsonian drug is desirable for patients who are having swallowing difficulty. The syrup of UK-738 is suitable for this purpose.

This publication has 0 references indexed in Scilit: